BRAIN Biotech publishes first ESG and Sustainability Report
BRAIN Biotech AG has published its first ESG and sustainability report. The company, which already directly addresses at least five UN Sustainable Development Goals (SDGs) with its products and solutions, sees the accelerated development towards sustainable business as a clear opportunity for the company's further development.
The BRAIN Group companies develop innovative products and services based on enzymes, microorganisms and bioactive natural compounds that help drive the economic transformation towards a sustainable circular economy. In addition to a detailed presentation of the company's sustainability strategy, the sustainability report also contains numerous examples of developments, products and cooperations from the BRAIN Group that are already helping industrial partners to achieve their own sustainability goals more quickly, or will do so in the future. With breakthrough innovations from its own incubator, the BRAIN Group can also make a significant contribution to sustainability in society.
Extensive ESG and impact analysis
The report is based on a comprehensive stocktaking. An ESG team spanning the BRAIN Group has identified and developed the most important topics for BRAIN's stakeholders and derived opportunities and risks for future corporate development from this.
Material ESG issues are of central importance for the business model and also the long-term financial success of BRAIN Biotech. They form an integral part of the company's risk assessment and planning. In addition to the economic and impact topics in focus for the BRAIN Group, the internal ESG analysis has led to the following material topics: strong corporate governance and business ethics, occupational health and safety, IP protection, talent development and product safety.
BRAIN Biotech follows established national and international guidelines in its strategy for sustainable corporate development and reporting. Reporting is based on standards such as the German Sustainability Code, the UN Global Compact, the Sustainable Development Goals of the United Nations and the Global Reporting Initiative (GRI), and thus meets the increased requirement for transparent sustainability reporting.
Michael Schneiders, Head IR & Sustainability, summarizes: “Most employees at BRAIN have long been passionate about the vision of a bio-based economy, which has contributed to a strong identification with the company. Our sustainability report now provides a detailed insight into how BRAIN will actively contribute to a more sustainable life, both at product and organizational level.”
Sustainability goals formulated for 2032 and beyond
BRAIN has set itself ambitious targets for sustainable corporate development. In addition to environmental, social and governance issues, the strategy for sustainable value enhancement also includes economic and impact targets. The company will document its progress through an annual progress report within the framework of the UN Global Compact (Communication on Progress, COP).
Adriaan Moelker, CEO of BRAIN Biotech AG, leads BRAIN's ESG initiatives at board level. He says: “All companies must contribute to achieving the ambitious global and EU sustainability goals as part of their business activities. I am very pleased that we as BRAIN provide key technologies, scientific services and products, for example from the enzyme sector, for this purpose. Developing sustainable business is anchored in our DNA. We aim to make a difference, and do this profitably in close collaboration with our customers and partners. We truly aspire to help create a bio-based future, and the trend towards sustainability is strongly aligned with that aspiration.”
The Sustainability Report 2022 and the ESG Data Sheet 2022 are available online at https://www.brain-biotech.com/investors/esg
Press Image
About BRAIN
BRAIN Biotech AG is a leading European supplier of bio-based products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.
BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning).
Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.
BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 55,3 million in the fiscal year 2022/23.
For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.
Disclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.